AI Verdict
BSX has stronger fundamentals based on our AI analysis.
BSX vs CVS Fundamental Comparison
| Metric | BSX | CVS |
|---|---|---|
| Revenue | $20.1B | $402.1B |
| Net Income | $2.9B | $1.8B |
| Net Margin | 14.4% | 0.4% |
| ROE | 12.0% | 2.4% |
| ROA | 6.6% | 0.7% |
| Current Ratio | 1.62x | 0.84x |
| Debt/Equity | 0.46x | 0.85x |
| EPS | $1.94 | $1.39 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
BSX vs CVS: Frequently Asked Questions
Is BSX or CVS a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), BSX has stronger fundamentals. BSX is rated BUY (80% confidence) while CVS is rated HOLD (70% confidence). This is not investment advice.
How does BSX compare to CVS fundamentally?
BOSTON SCIENTIFIC CORP has ROE of 12.0% vs CVS HEALTH Corp's 2.4%. Net margins are 14.4% vs 0.4% respectively.
Which stock pays higher dividends, BSX or CVS?
BSX has a dividend yield of N/A or no dividend while CVS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in BSX or CVS for long term?
For long-term investing, consider that BSX has BUY rating with 80% confidence, while CVS has HOLD rating with 70% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about BSX vs CVS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For BSX vs CVS, the AI consensus favors BSX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.